Recombinant human JNK3 / MAPK10, protein kinase, 10 µg

Background: c-Jun N-terminal kinase (JNK) is a member of the family of serine and threonine mitogen-activated protein kinases (MAPK). Whereas JNK1 and JNK2 have a broad tissue distribution, JNK3 is primarily localized in CNS neurons, making it an attractive CNS drug target. Thus, JNK3 is involved in key mechanisms that effect neurological diseases including PD, AD and stroke. The kinase JNK3 is activated by the upstream kinases MKK4 and MKK7, by bis-phosphorylation of Thr and Tyr residues in the activation loop. Then, JNK is able to phosphorylate multiple targets, including transcription factors that belong to the activator protein-1 (AP-1) class, for example, c-Jun, anti-activating transcription factor-2 (ATF-2), JunB and JunD.

Recombinant human JNK3, (full length, amino acids M1-R426 (as in NCBI/Protein entry NP_620446.1), activated, untagged, expressed in E.coli

Theoretical MW : 48.47 kDa
Expression system: Sf9 cells
Storage buffer: 50 mM Hepes, pH 7.5; 100 mM NaCl, 5 mM DTT, 20% glycerol
Activation:with MKK7 / MEKK2
Protein concentration: 0.211 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MAFC membrane
Specific activity : 118,000 pmol/mg min

Entrez Gene ID: 5602
UniProtKB: P53779

Product specific literature

Resnick L1, Fennell M.(2004) "Targeting JNK3 for the treatment of neurodegenerative disorders."Drug Discov Today. 2004 Nov 1;9(21):932-9.

Antoniou X, Falconi M, Di Marino D, Borsello T. (2011) "JNK3 as a therapeutic target for neurodegenerative diseases."J Alzheimers Dis. 2011;24(4):633-42.